Anaveon
Basel, CH · 4 known investors
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells. The company is a late-stage preclinical biotech focused on precision biologics for immune-mediated disease.
Biotech
Founders & leadership
Investors · 4
Competitors · 3
by search overlapAbeona Therapeutics14 shared keywordsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Avernatx8 shared keywordsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Anavex Life Sciences7 shared keywordsAnavex develops investigational oral therapies, including ANAVEX2-73 (blarcamesine), that target SIGMAR1 activation and autophagy to address neurodegenerative and neurodevelopmental diseases such as Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Its drug candidates are in clinical trials.
Companies competing with Anaveon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Anaveon do?
- Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells. The company is a late-stage preclinical biotech focused on precision biologics for immune-mediated disease.
- Who are Anaveon's investors?
- Anaveon's investors include Novartis Venture Fund, Pfizer Venture Investments, Pontifax Venture Capital, Syncona.
- Where is Anaveon headquartered?
- Anaveon is headquartered in Basel, CH.